期刊文献+

Recombinant activated factor Ⅶ in hemophagocytic lymphohistiocytosis with disseminated intravascular coagulation 被引量:2

Recombinant activated factor Ⅶ in hemophagocytic lymphohistiocytosis with disseminated intravascular coagulation
原文传递
导出
摘要 Hemophagocytic lymphohistiocytosis (HLH) is a lifethreatening disorder due to hyperinflammation resulting in infiltration of different organs with extensive hemophagocytosis. Severe coagulopathy was one of the main reasons for death in HLH. Over secretion of plasminogen activator by activated macrophages leads to hyperfibrinolysis. We reported a 36-year-old woman who was diagnosed as HLH probably secondary to lymphoma. Massive bleeding from gut and retroperitoneal area were not able to be controlled by conventional hemostatic treatments. This patient received one dose recombinant activated factor Ⅶ (rFVlla) 3.6 mg (70 μg/kg). Hemostatic effect was achieved in 0.5 hour and lasted 24 hours. Prothrombin time (PT) and activated partial thromboplastin time (APTT) were quickly corrected to normal ranges.Fibrinogen level elevated from 0.5 g/L before using rFVIla to 1.8 g/L 20 hours after. Although dexamethasone and etopside were administrated to treat HLH, this patient died from septic shock after persistent neutropenia. This suggests that rFVlla may be effective in the management of intractable hemorrhage in patients with HLH. Hemophagocytic lymphohistiocytosis (HLH) is a lifethreatening disorder due to hyperinflammation resulting in infiltration of different organs with extensive hemophagocytosis. Severe coagulopathy was one of the main reasons for death in HLH. Over secretion of plasminogen activator by activated macrophages leads to hyperfibrinolysis. We reported a 36-year-old woman who was diagnosed as HLH probably secondary to lymphoma. Massive bleeding from gut and retroperitoneal area were not able to be controlled by conventional hemostatic treatments. This patient received one dose recombinant activated factor Ⅶ (rFVlla) 3.6 mg (70 μg/kg). Hemostatic effect was achieved in 0.5 hour and lasted 24 hours. Prothrombin time (PT) and activated partial thromboplastin time (APTT) were quickly corrected to normal ranges.Fibrinogen level elevated from 0.5 g/L before using rFVIla to 1.8 g/L 20 hours after. Although dexamethasone and etopside were administrated to treat HLH, this patient died from septic shock after persistent neutropenia. This suggests that rFVlla may be effective in the management of intractable hemorrhage in patients with HLH.
出处 《Chinese Medical Journal》 SCIE CAS CSCD 2011年第19期3189-3191,共3页 中华医学杂志(英文版)
关键词 recombinant factor VIIa hemaphagocytic lymphohistiocytosis disseminated intravascular coagulation recombinant factor VIIa hemaphagocytic lymphohistiocytosis disseminated intravascular coagulation
  • 相关文献

参考文献9

  • 1Henter JI,Home A,Arico M,Egeler RM,Filipovich AH,Imashuku S,et al.HLH-2004:diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis.Pediatr Blood Cancer 2007; 48:124-131.
  • 2Schneider EM,Lorenz I,Muller-Rosenberger M,Steinbach G,Kron M, Janka-Schaub GE. Hemophagocytic lymphohistiocytosis is associated with deficiencies of cellular cytolysis but normal expression of transcripts relevant to killer-cellinduced apoptosis.Blood 2002; 100:2891-2898.
  • 3Henter JI,Elinder G,S(o)der O,Hansson M,Andersson B,Andersson U.Hypercytokinemia in familial hemophagocytic lymphohistiocytosis.Blood 1991; 78:2918-2922.
  • 4Janka GE,Schneider EM.Modem management of children with hemophagocytic lymphohistiocytosis.Br J Hematol 2004; 124:4-14.
  • 5Lisman T,De Groot PHG.Mechanism of action of recombinant factor Ⅶa.J Thromb Haemost 2003; 1:1138-1139.
  • 6Hedner U.Treatment of patients with factor Ⅷ and factor Ⅸ inhibitors with special focus on the use of recombinant factor Ⅶa.Thromb Haemost 1999; 82:531-539.
  • 7Hsia CC,Chin-Yee IH,McAlister VC.Use of recombinant activated factor Ⅶ in patients without hemophilia a meta-analysis of randomized control trials.Ann Surg 2008;248:61-68.
  • 8Celkan T,Alhaj S,Civilibal M,Elicevik M.Control of bleeding associated with hemophagocytic syndrome in children:an audit of the clinical use of recombinant acitivated factor Ⅶ.Pediatr Hematol Oncol 2007; 24:117-121.
  • 9Miller CG,Stringer MD,Sugarman I,Richards M.The use of recombinant factor VIIa for bleeding in paediatric practice.Hemophilia 2005; 11:171-174.

同被引文献17

引证文献2

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部